Peer Exchange

March 01, 2019 –

Panelists share their personal experiences with biologics and the benefit of pathways.

March 01, 2019 –

Experts provide final thoughts on treatment and asthma.

February 22, 2019 –

Experts review the IL-5–inhibiting agents mepolizumab, benralizumab, and reslizumab.

February 22, 2019 –

Experts provide an overview of dupilumab, including mechanism of action, dosing, and pivotal trials.

February 19, 2019 –

Kate Jeffers, PharmD, sums up the importance of patient adherence with CDK4/6 inhibitors and quality metrics used to measure adherence.

February 15, 2019 –

Define unmanaged/uncontrolled severe asthma and provide an overview of the available biologics.

February 15, 2019 –

A review of Omalizumab’s adverse effects, mechanism, and ideal patient factors.

February 12, 2019 –

Important touchpoints for patient management of CDK4/6 inhibitors.

February 12, 2019 –

Outlining different dispensing options for CDK4/6 inhibitors including in-clinic, specialty, and medically integrated dispensing.

February 08, 2019 –

A discussion on the biomarkers used to determine efficacy with specific biologics.

Sign In